Adhera Therapeutics Inc (ATRX) Com Stk USD0.006
Adhera Therapeutics, Inc., formerly Marina Biotech, Inc., is a specialty pharmaceutical company that provides patient centric treatment for hypertension. The Company develops and commercializes pharmaceutical therapies and provides technology to improve patient outcomes. It is also focused on developing and commercializing late-stage, non-addictive pain therapeutics. It provides Celecoxib-Lisinopril fixed dose combination (IT-102) and Celecoxib-Olmesartan fixed dose combination (IT-103), which are designed to control the side-effect of edema that prohibits the drug from being prescribed at higher doses. IT-102 targets a population requiring angiotensin converting enzyme (ACE) inhibitors, such as lisinopril and IT-103 targets a population requiring olmesartan. The Company is also focused on commercializing perindopril arginine and amlodipine besylate (PRESTALIA) through DyrctAxess, which is a patient-centric treatment platform.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.